Literature DB >> 24259691

Missed drug therapy alerts as a consequence of incomplete electronic patient records in Dutch community pharmacies.

Annemieke Floor-Schreudering1, Mette Heringa, Henk Buurma, Marcel L Bouvy, Peter A G M De Smet.   

Abstract

BACKGROUND: Complete and up-to-date medical and pharmaceutical information in the electronic patient record (EPR) is a prerequisite for risk management in community pharmacy.
OBJECTIVES: To analyze which information is missing in the EPR and which drug therapy alerts, therefore, fail to appear.
METHODS: Pharmacy students selected patients who were dispensed a prescription drug and enlisted for >3 months in the participating pharmacies. Patients received a questionnaire in which they were asked to verify their medication history, and to provide additional patient information. For each enrolled patient, the students collected all relevant information from the EPR. Self-reported data from the patient were compared with data retrieved from the EPR. Missed information in the EPR was evaluated based on national professional guidelines.
RESULTS: Questionnaires were received from 67% of the selected patients (442/660). Prescription drugs were missing in the EPR of 14% of the 442 patients, nonprescription drugs in 44%, diseases in 83%, and intolerabilities in 16%. In 38% of the patients (166/442), drug therapy alerts failed to appear because of missing information: drug-disease interactions in 34% of the patients, duplicate medications in 4%, drug-drug interactions (DDIs) in 4%, and drug intolerabilities in 2%. Among the (non-)prescription drugs missing, NSAIDs were most frequently responsible for the missed alerts. Diseases most frequently associated with missed alerts were gastroesophageal reflux disease, renal insufficiency, asthma/chronic obstructive pulmonary disease, and heart failure.
CONCLUSIONS: Relevant patient information was frequently missing in the EPRs. The nonappearance of drug therapy alerts may have had clinical consequences for patients.

Entities:  

Keywords:  automated drug alerts; clinical risk management; community pharmacy services; drug safety alerts; electronic patient record; pharmacy information systems

Mesh:

Year:  2013        PMID: 24259691     DOI: 10.1177/1060028013501992

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Enabling claims-based decision support through non-interruptive capture of admission diagnoses and provider billing codes.

Authors:  Colin G Walsh; David K Vawdrey; Peter D Stetson; Matthew R Fred; George Hripcsak
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

2.  Considerations of prescribers and pharmacists for the use of non-selective β-blockers in asthma and COPD patients: An explorative study.

Authors:  Esther Kuipers; Michel Wensing; Peter A G M De Smet; Martina Teichert
Journal:  J Eval Clin Pract       Date:  2018-01-10       Impact factor: 2.431

3.  The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion.

Authors:  Justine M Z van Tongeren; S Froukje Harkes-Idzinga; Heleen van der Sijs; Roya Atiqi; Bart J F van den Bemt; L Willem Draijer; Deline Hiel; Adrian Kerremans; Bart Kremers; Marc de Leeuw; Marleen V Olthoff; T Kim-Loan Pham; Ricky Valentijn-Robertz; Kayan Tsoi; Iris Wichers; Maaike de Wit; Sander D Borgsteede
Journal:  Front Pharmacol       Date:  2020-05-15       Impact factor: 5.810

4.  Clinical Decision Support and Optional Point of Care Testing of Renal Function for Safe Use of Antibiotics in Elderly Patients: A Retrospective Study in Community Pharmacy Practice.

Authors:  Mette Heringa; Annemieke Floor-Schreudering; Peter A G M De Smet; Marcel L Bouvy
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

5.  Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy.

Authors:  Paula Bachmann; Niklas Frahm; Jane Louisa Debus; Pegah Mashhadiakbar; Silvan Elias Langhorst; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Michael Hecker; Uwe Klaus Zettl
Journal:  Pharmaceutics       Date:  2022-03-08       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.